Researchers shed light on the immunometabolism of respiratory infection, providing an avenue towards safer COVID-19 therapeutics for those affected by metabolic disorders.
A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.